艾迪药业(688488.SH)：ADC118片获得药物临床试验批准通知书

Core Viewpoint - The company, Aidi Pharmaceutical (688488.SH), has received approval from the National Medical Products Administration for clinical trials of its new drug ADC118 in the field of HIV treatment [1] Group 1 - Aidi Pharmaceutical and its wholly-owned subsidiaries, Chengdu Aidi Pharmaceutical Technology Co., Ltd. and Nanjing Aidi Pharmaceutical Technology Co., Ltd., have been granted a clinical trial approval notice [1] - The approval was issued on October 28, 2025, allowing the company to proceed with clinical trials for its investigational first-class new drug ADC118 [1]